Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1072250 | 0.98 | ALDH1A1 (0.33) | KEAP1NFE2L2ALDH1A1EPHX1 | |
| SCHEMBL29889579 | 0.76 | KEAP1 (0.35) | KEAP1NFE2L2EPHX1 | |
| SCHEMBL8196191 | 0.75 | KEAP1 (0.33) | KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL4310017 | 0.71 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL9795387 | 0.71 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL9067197 | 0.70 | ALDH1A1 (0.35) | ALDH1A1EPHX1 | |
| SCHEMBL10790172 | 0.68 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL4209005 | 0.68 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL4728809 | 0.68 | KEAP1 (0.41) | KEAP1NFE2L2ALDH1A1EPHX1 | |
| SCHEMBL6255794 | 0.68 | KEAP1 (0.41) | KEAP1NFE2L2ALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271345-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-05-20 | — | — | EP | disclosed |
| US-20140296136-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-02 | — | — | US | disclosed |
| US-8846291-B2 | Resist composition, method of forming resist pattern, and new compound | TOKYO OHKA KOGYO CO. LTD. (JP) | 2014-09-30 | — | — | US | disclosed |
| US-20110046161-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046161-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | KEAP1 67/4885NFE2L2 868/4885ALDH1A1 1199/4885 |
| US-20140296136-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | KEAP1 67/4885NFE2L2 868/4885ALDH1A1 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.